CN103304549B - Jaspine B、3-epi Jaspine B三氮唑类衍生物、其制备方法及其应用 - Google Patents
Jaspine B、3-epi Jaspine B三氮唑类衍生物、其制备方法及其应用 Download PDFInfo
- Publication number
- CN103304549B CN103304549B CN201310278916.9A CN201310278916A CN103304549B CN 103304549 B CN103304549 B CN 103304549B CN 201310278916 A CN201310278916 A CN 201310278916A CN 103304549 B CN103304549 B CN 103304549B
- Authority
- CN
- China
- Prior art keywords
- compound
- nitrine
- solvent
- jaspine
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[N+]/C=C(\CO/C=C(\C1)/OCC1=*)/NN Chemical compound C[N+]/C=C(\CO/C=C(\C1)/OCC1=*)/NN 0.000 description 4
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一类Jaspine B、3-epi Jaspine B三氮唑类衍生物、其合成方法及其药物用途,属于药物化学领域。其具有如下结构通式:
Description
技术领域
本发明涉及Jaspine B、3-epi Jaspine B三氮唑类化合物、其合成方法及药物用途,属于药物化学领域。
背景技术
目前有报道发现,Jaspine B对白血病细胞P388、肺癌细胞A549、结肠癌细胞HT29和黑色素瘤细胞SK-Mel28等细胞在0.01μg/mL就显示细胞毒活性。2009年Andrieu-Abadie等人报道Jaspine B通过调控鞘磷脂合酶的活性,进而调控神经酰胺的形成并激活caspase通路,引起细胞凋亡,在体外实验中Jaspine B表现出对黑色素瘤细胞SK-Mel28时间和浓度依赖性的抑制作用。2011年Oishi等人发现Jaspine B和它的立体异构体能够抑制SphK1和SphK2,从而调控神经酰胺的形成并激活caspase通路,引起细胞凋亡。以上研究表明,Jaspine B是一种优良的鞘氨醇激酶和鞘磷脂合酶抑制剂,能够调节神经鞘胺醇含量,控制肿瘤的生长和凋亡。
Jaspine B需从Pachastrissa sp.或者Jaspissp.中分离提取,但提取工作操作繁琐,收率低。由于其独特的抗肿瘤作用机制和很高的抗肿瘤活性,研究Jaspine B及其类似物的合成方法不仅具有重要的科学意义,而且对研究构效关系,发现具有抗肿瘤活性的化合物具有重要的实际应用价值。
2011年本发明人以木糖为起始原料合成出Jaspine B关键中间体(刘宏民,赵明礼,高洁,张召,抗肿瘤活性天然产物Jaspine B 和3-epi Jaspine B 关键中间体的合成方法,CN102382081A)。且文献报道,三氮唑结构易于引入分子中,且生物活性较好。若在Jaspine B长的侧链中引入三氮唑杂环合成出一系列衍生物,或许能筛选出与Jaspine B相当或者更好的活性化合物,值得研究和关注。
发明内容
基于上述,本发明目的之一是提供一类新的具有抗肿瘤活性的Jaspine B、3-epi Jaspine B三氮唑类化合物;目的之二是提供该类化合物的制备方法;目的之三是提供该类化合物在制备抗肿瘤药物方面的应用。
本发明所述的Jaspine B、3-epi Jaspine B三氮唑类化合物具有以下结构通式:
其中n为6、7、8、9、11、13、15、17。
首先制备Jaspine B三氮唑类衍生物5a-5h,制备Jaspine B三氮唑类衍生物5a-5h的方法通过以下步骤实现:(1)在溶剂中将化合物1还原得到化合物2,所用到的还原剂为KBH4或NaBH4, 所选用的溶剂为甲醇或乙醇;(2) 溶剂中,化合物2在碱性条件下与溴丙炔反应得到化合物3,所用的碱为NaOH、KOH或K2CO3,所选用的溶剂为乙氰;(3)化合物3先在三苯基膦,四氢呋喃水的体系下还原叠氮基团,再用Boc保护氨基得到化合物4;(4)将化合物4在催化剂的作用下与不同链长的烷基叠氮反应,得到化合物5a-5h。催化剂选择抗坏血酸钠与无水硫酸铜,碘化亚铜,溶剂选择四氢呋喃与水。
首先制备3-epi Jaspine B三氮唑类衍生物5'a-5'h,制备3-epi Jaspine B三氮唑类衍生物5'a-5'h的方法通过以下步骤实现:(1)在溶剂中将化合物1′还原得到化合物2′,所用到的还原剂为KBH4或NaBH4, 所选用的溶剂为甲醇或乙醇;(2)溶剂中,化合物2′在碱性条件下与溴丙炔反应得到化合物3′,所用的碱为NaOH、 KOH或K2CO3,所选用的溶剂为乙氰;(3)化合物3′先在三苯基膦,四氢呋喃水的体系下还原叠氮基团,再用Boc保护氨基得到化合物4′;(4)将化合物4′在催化剂的作用下与不同链长的烷基叠氮反应,得到化合物5′a-5′h。催化剂选择抗坏血酸钠与无水硫酸铜或碘化亚铜,溶剂选择四氢呋喃与水。
所述烷基叠氮优选庚烷叠氮、辛烷叠氮、壬烷叠氮、癸烷叠氮、十二烷基叠氮、十四烷基叠氮、十六烷基叠氮、十八烷基叠氮。
其次,制备Jaspine B三氮唑类衍生物6a-6h:溶剂中,将化合物5a-5h在酸的作用下以及催化剂的作用下合成化合物6a-6h;所述溶剂选自甲醇、乙醇或乙酸乙酯;酸选自盐酸或三氟乙酸,催化剂选择Pd/C, Pd(OH)2 。
其次,制备3-epi Jaspine B三氮唑类衍生物6'a-6'h:溶剂中,将化合物5'a-5'h在酸的作用下以及催化剂的作用下合成化合物6'a-6'h;所述溶剂选自甲醇、乙醇或乙酸乙酯;酸选自盐酸或三氟乙酸,催化剂选择Pd/C, Pd(OH)2 。
将本发明合成的Jaspine B、3-epi Jaspine B化合物6a-6h、6'a-6'h用于制备抗肿瘤药物中。采用四噻唑蓝 (MTT) 法评价化合物6a-6h、6'a-6'h对EC9706、MGC-803、MCF-803三株肿瘤细胞增殖的抑制作用。
本发明合成的化合物具有较好的抗肿瘤活性,其副作用较小;原料简单易得,合成方法简单可行,收率较高,为新型抗肿瘤药物的开发提供筛选药物。以其为活性成份,将其用于制备治疗乳腺癌、食管癌、胃癌、前列腺癌、子宫癌、卵巢癌、子宫颈癌、结肠癌、直肠癌、甲状腺癌、肺癌、肝癌、甲状腺癌、睾丸癌、肾癌、膀胱癌、小肠癌、胰腺癌或白血病药物中。尤其是制备治疗乳腺癌、食管癌或胃癌药物中。
具体实施方式
通过以下实施实例对本发明作进一步的说明,但不作为限制。
1. 化合物2和2′的合成通法
称取化合物1(2 mmol)置于25ml圆底烧瓶中,用质量百分比95%乙醇溶解,冰浴,将硼氢化钾(3 mmol)平均分成五次加入反应体系,每次间隔5分钟,然后撤去冰浴升至室温,常温搅拌1小时,TLC检测(石油醚:丙酮=2:1)反应完全,再冰浴,加入氯化铵固体至不再有气泡为止,然后过滤除去固体,将滤液浓缩,用乙酸乙酯溶解,然后用饱和食盐水萃取,无水硫酸钠干燥,抽滤,减压蒸干得到粗品,然后用硅胶柱层析分离(石油醚:乙酸乙酯=8:1)得纯品化合物2,产率95%。1H NMR (400 MHz, CDCl3) δ 7.47 – 7.33 (m, 5H), 4.84 (d, J = 11.6 Hz, 1H), 4.59 (d, J = 11.6 Hz, 1H), 4.37 – 4.28 (m, 1H), 4.08 (d, J = 5.5 Hz, 1H), 3.99 (dd, J = 9.7, 6.1 Hz, 2H), 3.95 – 3.90 (m, 1H), 3.84 (d, J = 4.0 Hz, 2H), 2.31 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 136.98, 128.71, 128.33, 127.94, 79.95, 79.56, 73.86, 69.38, 61.83, 61.22. HRMS: calcd for C12H15N3O3Na [M+Na]+272.1108, found 272.1110.
化合物2′,黄色油状物: 1H NMR (400 MHz, CDCl3, ppm) : δ 7.41 – 7.29 (m, 5H), 4.60 (q, J = 11.7 Hz, 2H), 4.06 – 3.98 (m, 2H), 3.98 – 3.88 (m, 3H), 3.83 – 3.75 (m, 1H), 3.65 (ddd, J = 11.8, 6.9, 5.0 Hz, 1H), 2.25 (d, J = 5.5 Hz, 1H).13C NMR (100 MHz, CDCl3, ppm) : δ 137.1, 128.6, 128.20, 127.87, 84.84, 84.20, 72.54, 71.03, 65.94, 62.33.
2. 化合物3和3′的合成通法
取化合物2(15 mmol)于150mL的圆底烧瓶中,加入乙腈将其溶解,加入NaOH (20 mmol),慢慢向反应体系中滴加溴丙炔(18mmol),加完之后将体系置于80℃的油浴中加热回流4h。TLC检测(石油醚:乙酸乙酯=3:1),反应完毕后,铺一层薄薄的硅胶将固体滤去,旋干,用乙酸乙酯溶解,饱和食盐水洗, 无水硫酸镁干燥, 抽滤除去硫酸镁,将滤液蒸干得到红褐色油状物, 将粗品柱层析分离(石油醚:乙酸乙酯=10:1), 得到化合物3,产率83%。 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.32 (m, 5H), 4.82 (d, J = 11.6 Hz, 1H), 4.65 (d, J = 11.6 Hz, 1H), 4.28 – 4.21 (m, 2H), 4.17 (ddd, J = 9.9, 6.3, 2.2 Hz, 2H), 4.00 – 3.95 (m, 2H), 3.95 – 3.89 (m, 1H), 3.85 – 3.79 (m, 1H), 3.73 (dd, J = 10.1, 7.3 Hz, 1H), 2.45 (t, J = 2.4 Hz, 1H).13C NMR (101 MHz, CDCl3) δ 137.36, 128.52, 128.06, 127.93, 79.52, 79.47, 79.11, 74.69, 73.91, 69.03, 68.64, 61.23, 58.63.
化合物3′, 黄色油状物: 1H NMR (400 MHz, CDCl3, ppm) : δ 7.44 – 7.30 (m, 5H), 4.68 – 4.58 (m, 2H), 4.23 (d, J = 2.4 Hz, 2H), 4.03 (ddd, J = 17.9, 7.8, 3.8 Hz, 4H), 3.96 (d, J = 4.5 Hz, 1H), 3.69 (d, J = 5.2 Hz, 2H), 2.47 (dd, J = 2.8, 1.7 Hz, 1H).13C NMR (100 MHz, CDCl3, ppm) : δ 137.23, 128.58, 128.10, 127.89, 84.80, 83.05, 79.34, 74.89, 72.34, 70.95, 69.39, 65.76, 58.66.
3. 化合物4和4′的合成通法
取化合物3(2 mmol)于圆底烧瓶中,先用THF/H2O体系溶解,加入PPh3(12 mmol),加热回流4h, 反应完之后蒸干溶剂,再加入一定量的THF溶解,再加入Boc酸酐 (6 mmol), 常温下搅拌2 h,TLC检测(石油醚:乙酸乙酯=1:1),反应完毕后,旋干,用乙酸乙酯溶解,饱和NaHCO3洗两次,再用饱和食盐水洗3次,无水硫酸镁干燥,抽滤除去硫酸镁,将滤液蒸干得到无色透明油状物,柱层析(石油醚:乙酸乙酯=10:1)得到化合物4,两步产率86%;1H NMR (400 MHz, CDCl3, ppm): δ 7.39 – 7.30 (m, 5H), 5.38 (d, J = 8.8 Hz, 1H), 4.78 (d, J = 11.9 Hz, 1H), 4.58 (d, J = 11.9 Hz, 1H), 4.28 – 4.14 (m, 3H), 3.99 (dd, J = 9.2, 3.7 Hz, 2H), 3.90 – 3.84 (m, 2H), 3.69 (qd, J = 10.4, 3.0 Hz, 2H), 2.43 (s, 1H), 1.47 (s, 9H). 13C NMR (100 MHz, CDCl3, ppm) : δ 155.37, 137.72, 128.45, 127.86, 127.79, 85.57, 83.85, 79.45, 78.93, 75.09, 73.08, 71.70, 69.67, 58.73, 55.69, 28.42. HRMS (IES) : calcd for C20H27NO5Na [M+Na]+: 384.1787, found 384.1785.
化合物4′,黄色固体,Mp: 54-55℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.39 – 7.30 (m, 5H), 5.38 (d, J = 8.8 Hz, 1H), 4.78 (d, J = 11.9 Hz, 1H), 4.58 (d, J = 11.9 Hz, 1H), 4.28 – 4.14 (m, 3H), 3.99 (dd, J = 9.2, 3.7 Hz, 2H), 3.90 – 3.84 (m, 2H), 3.69 (qd, J = 10.4, 3.0 Hz, 2H), 2.43 (s, 1H), 1.47 (s, 9H). 13C NMR (100 MHz, CDCl3, ppm) : δ 155.37, 137.75, 128.43, 127.84, 127.77, 85.60, 83.84, 78.95, 77.67, 75.05, 73.04, 71.70, 69.69, 67.91, 58.72, 28.40. HRMS (IES) : calcd for C20H27NO5Na [M+Na]+: 384.1787, found 384.1789.
4. 化合物5a-5h的合成通式
取化合物4(0.1mmol)于圆底烧瓶中,先用THF溶液溶解,再加入水,加入抗坏血酸钠(0.024mmol),再加入无水硫酸铜(0.02mmol), 常温下搅拌十分钟,至体系澄清,再慢慢滴加烷基叠氮(0.15mmol)的THF溶液,室温下搅拌1h,TLC检测(石油醚:乙酸乙酯=1:1),反应完毕后,旋干,乙酸乙酯溶解,饱和食盐水洗3次,乙酸乙酯反萃2次,无水硫酸镁干燥。抽滤除去硫酸镁,将滤液蒸干,柱层析(石油醚:乙酸乙酯=3:1),得到化合物5,产率介于75%-90%之间。
5、化合物5'a-5'h合成通法
取化合物4' (0.1mmol)于圆底烧瓶中,先用THF溶液溶解,再加入水,加入抗坏血酸钠(0.024mmol),再加入无水硫酸铜0.02mmol, 常温下搅拌十分钟,至体系澄清,再慢慢滴加烷基叠氮(0.15mmol)的THF溶液,室温下搅拌1h,TLC检测(石油醚:乙酸乙酯=1:1),反应完毕后,旋干,乙酸乙酯溶解,饱和食盐水洗3次,乙酸乙酯反萃2次,无水硫酸镁干燥。抽滤除去硫酸镁,将滤液蒸干,柱层析(石油醚:乙酸乙酯=3:1),得到化合物5',产率介于70%-90%之间。
本实施合成了系列化合物5a-5h和5'a-5'h,如表1
表1
6、化合物6a-6h合成通法
取化合物5(0.31 mmol),用甲醇将化合物5溶解,加入5 %的Pd/C催化,再滴加入37.5 %浓盐酸,60℃,50 atm下加氢脱苄基并脱去Boc保护基,反应4h,TLC检测(乙酸乙酯:甲醇 =20 : 1),反应完毕后,蒸干得到粗品,柱层析(乙酸乙酯:甲醇=7 : 1), 得到化合物6,产率介于75 %-85 %。
7. 化合物6'a-6'h合成通法
取化合物5' (0.31mmol),用甲醇将化合物5' 溶解,加入5 %的Pd/C催化,再滴加入37.5 % 浓盐酸,60 ℃,50 atm下加氢脱苄基并脱去Boc保护基,反应4h,TLC检测(乙酸乙酯:甲醇 =20 : 1),反应完毕后,蒸干得到粗品,柱层析(乙酸乙酯:甲醇=7 : 1),得到化合物6', 产率介于75 %-85 %之间。
本实施合成了系列化合物6a-6h和6'a-6'h,如表2:
表2
表1中化合物的核磁数据选择性表述如下:
5a 白色粉末状固体,Mp: 48-49℃; 1H NMR (400 MHz, CDCl3, ppm) : δ7.49 (s, 1H), 7.45 – 7.31 (m, 5H), 5.40 (d, J = 8.7 Hz, 1H), 4.72 (s, 2H), 4.57 (q, J = 11.6 Hz, 2H), 4.42 – 4.34 (m, 1H), 4.27 (td, J = 7.0, 1.5 Hz, 2H), 4.18 – 4.09 (m, 2H), 3.93 (dd, J = 8.7, 6.6 Hz, 1H), 3.79 – 3.65 (m, 3H), 1.86 (p, J = 7.2 Hz, 2H), 1.42 (d, J = 13.0 Hz, 9H), 1.37 – 1.23 (m, 8H), 0.89 (t, J = 6.9 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm): δ 155.69, 144.80, 137.62, 128.54, 128.00, 127.85, 122.26, 79.51, 79.25, 78.22, 73.72, 71.09, 68.86, 65.13, 52.03, 50.32, 31.55, 30.29, 28.65, 28.38, 26.44, 22.51, 14.02. HRMS (IES) : m/z calcd for C27H42N4O5Na (M+Na)+, 525.3053; found 525.3054.
5b 白色粉末状固体,Mp: 53-54℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.49 (s, 1H), 7.43 – 7.31 (m, 5H), 5.40 (d, J = 8.7 Hz, 1H), 4.72 (s, 2H), 4.58 (q, J = 11.6 Hz, 2H), 4.42 – 4.35 (m, 1H), 4.31 – 4.23 (m, 2H), 4.14 (td, J = 10.4, 5.5 Hz, 2H), 3.94 (dd, J = 8.7, 6.7 Hz, 1H), 3.79 – 3.67 (m, 3H), 1.91 – 1.82 (m, 2H), 1.44 (s, 9H), 1.35 – 1.24 (m, 10H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm): δ 155.70, 144.82, 137.62, 128.55, 128.00, 127.86, 122.27, 79.53, 79.26, 78.23, 73.73, 71.09, 68.87, 65.12, 52.04, 50.33, 31.70, 30.30, 29.70, 29.04, 28.95, 28.39, 26.49, 22.59, 14.06. HRMS (IES) : m/z calcd for C28H44N4O5Na (M+Na)+: 539.3209; found, 539.3207.
5c 淡粉色粉末状固体,Mp: 49-50℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.49 (s, 1H), 7.43 – 7.30 (m, 5H), 5.40 (d, J = 8.7 Hz, 1H), 4.72 (s, 2H), 4.66 – 4.49 (m, 2H), 4.44 – 4.34 (m, 1H), 4.28 (dt, J = 7.6, 6.1 Hz, 2H), 4.20 – 4.08 (m, 2H), 3.93 (dd, J = 8.8, 6.6 Hz, 1H), 3.81 – 3.64 (m, 3H), 1.91 – 1.79 (m, 2H), 1.45 (d, J = 11.9 Hz, 9H), 1.36 – 1.20 (m, 12H), 0.89 (dd, J = 9.0, 4.7 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) :δ 155.69, 144.85, 137.63, 128.54, 127.99, 127.85, 122.26, 79.50, 79.26, 78.23, 73.72, 71.10, 68.86, 65.14, 52.04, 50.32, 31.79, 30.30, 29.33, 29.16, 28.99, 28.38, 26.49, 22.63, 14.09. HRMS (IES) : m/z calcd for C29H46N4O5 Na (M+ Na)+: 553.3366; found, 553.3364.
5d 白色粉末状固体,Mp: 66-67℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.49 (s, 1H), 7.36 (dt, J = 14.0, 5.0 Hz, 5H), 5.41 (d, J = 8.8 Hz, 1H), 4.71 (s, 2H), 4.57 (q, J = 11.6 Hz, 2H), 4.37 (dd, J = 14.2, 7.1 Hz, 1H), 4.33 – 4.21 (m, 2H), 4.19 – 4.04 (m, 2H), 3.93 (dd, J = 8.6, 6.7 Hz, 1H), 3.79 – 3.63 (m, 3H), 1.94 – 1.80 (m, 2H), 1.44 (d, J = 6.1 Hz, 9H), 1.35 – 1.21 (m, 14H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm): δ 155.70, 137.62, 128.54, 127.99, 127.95, 127.85, 122.27, 79.51, 79.25, 78.22, 73.72, 71.08, 68.86, 65.12, 52.03, 50.33, 31.84, 30.29, 29.46, 29.37, 29.24, 28.99, 28.38, 26.49, 22.66, 14.10. HRMS (IES) : m/z calcd for C30H48N4O5Na (M+Na)+: 567.3522; found, 567.3524.
5e 白色粉末状固体,Mp:63-64℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.44 (s, 1H), 7.40 – 7.31 (m, 5H), 5.36 (d, J = 8.8 Hz, 1H), 4.72 (s, 2H), 4.57 (q, J = 11.6 Hz, 2H), 4.43 – 4.34 (m, 1H), 4.27 (dd, J = 7.6, 5.9 Hz, 2H), 4.19 – 4.10 (m, 2H), 3.98 – 3.88 (m, 1H), 3.78 – 3.68 (m, 3H), 1.90 – 1.81 (m, 2H), 1.45 (d, J = 6.7 Hz, 9H), 1.29 (d, J = 18.9 Hz, 22H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm): δ 155.69, 144.82, 137.62, 128.55, 128.00, 127.86, 122.24, 79.51, 79.26, 78.23, 73.72, 71.10, 68.87, 65.15, 52.04, 50.32, 31.90, 30.31, 29.60, 29.52, 29.39, 29.33, 29.01, 28.39, 26.51, 22.69, 14.12. HRMS (IES) : m/z calcd for C32H52N4O5Na (M+Na)+: 595.3835; found, 595.3835.
5f. 白色粉末状固体,Mp: 67-68℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.49 (s, 1H), 7.42 – 7.30 (m, 5H), 5.40 (d, J = 8.8 Hz, 1H), 4.72 (s, 2H), 4.57 (q, J = 11.6 Hz, 2H), 4.42 – 4.34 (m, 1H), 4.27 (dd, J = 7.6, 5.9 Hz, 2H), 4.19 – 4.08 (m, 2H), 3.98 – 3.86 (m, 1H), 3.79 – 3.65 (m, 3H), 1.92 – 1.81 (m, 2H), 1.45 (d, J = 6.7 Hz, 9H), 1.29 (d, J = 18.9 Hz, 22H), 0.89 (t, J = 6.8 Hz, 3H).13C NMR (100 MHz, CDCl3, ppm): δ 155.69, 144.81, 137.62, 128.54, 128.00, 127.85, 122.24, 79.50, 79.25, 78.22, 73.72, 71.16, 71.09, 68.86, 65.14, 52.03, 50.32, 31.92, 30.31, 29.67, 29.64, 29.60, 29.52, 29.39, 29.35, 29.01, 28.38, 26.50, 22.69, 14.13. HRMS (IES) : m/z calcd for C34H56N4O5Na (M+Na)+: 623.4148; found, 623.4147.
5g 白色粉末状固体,Mp:70-71℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.49 (s, 1H), 7.42 – 7.31 (m, 5H), 5.40 (d, J = 8.7 Hz, 1H), 4.72 (s, 2H), 4.58 (q, J = 11.6 Hz, 2H), 4.46 – 4.33 (m, 1H), 4.32 – 4.23 (m, 2H), 4.18 – 4.10 (m, 2H), 3.94 (dd, J = 8.7, 6.7 Hz, 1H), 3.78 – 3.69 (m, 3H), 1.91 – 1.82 (m, 2H), 1.44 (s, 3H), 1.29 (d, J = 19.0 Hz, 9H), 0.90 (t, J = 6.8 Hz, 1H). 13C NMR (100 MHz, CDCl3, ppm): δ 155.69, 144.81, 137.62, 128.55, 128.00, 127.86, 122.24, 79.51, 79.25, 78.22, 73.72, 71.10, 68.86, 65.15, 52.03, 50.32, 31.93, 30.31, 29.69, 29.66, 29.61, 29.53, 29.39, 29.37, 29.01, 28.39, 26.51, 22.70, 14.13. HRMS (IES) : m/z calcd for C36H61N4O5Na (M+Na)+: 651.4456; found, 651.4464.
5h 白色粉末状固体,Mp:81-82℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.49 (s, 1H), 7.44 – 7.31 (m, 5H), 5.40 (d, J = 8.6 Hz, 1H), 4.72 (s, 2H), 4.58 (q, J = 11.6 Hz, 2H), 4.44 – 4.34 (m, 1H), 4.27 (dd, J = 7.6, 5.8 Hz, 2H), 4.18 – 4.11 (m, 2H), 3.94 (dd, J = 8.7, 6.7 Hz, 1H), 3.78 – 3.66 (m, 3H), 1.91 – 1.82 (m, 2H), 1.44 (s, 9H), 1.29 (d, J = 17.0 Hz, 30H), 0.90 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm): δ 155.69, 144.81, 137.62, 128.54, 128.00, 127.86, 122.24, 79.25, 78.23, 73.72, 71.10, 68.87, 65.15, 52.03, 50.32, 31.93, 30.31, 29.70, 29.66, 29.61, 29.54, 29.40, 29.37, 29.02, 28.39, 26.51, 22.70, 14.13. HRMS (IES) : m/z calcd for C38H64N4O5Na(M+Na)+: 679.4774; found, 679.4778.
5'a 淡粉色粉末状固体,Mp: 50-51℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.52 (s, 1H), 7.34 (s, 5H), 5.43 (d, J = 8.6 Hz, 1H), 4.72 (dt, J = 17.4, 9.1 Hz, 3H), 4.55 (d, J = 11.8 Hz, 1H), 4.34 (t, J = 7.3 Hz, 2H), 4.26 – 4.18 (m, 1H), 4.05 – 3.94 (m, 2H), 3.90 – 3.77 (m, 2H), 3.74 (d, J = 10.6 Hz, 1H), 3.64 (dd, J = 10.5, 3.6 Hz, 1H), 1.98 – 1.82 (m, 2H), 1.45 (s, 9H), 1.31 (ddd, J = 9.6, 6.4, 4.0 Hz, 8H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 155.29, 144.45, 137.70, 128.42, 127.81, 122.22, 85.71, 83.97, 79.43, 73.03, 71.71, 70.56, 65.09, 55.81, 50.40, 31.55, 30.33, 28.65, 28.42, 26.46, 22.51, 14.01. HRMS (IES) : m/z calcd for C27H42N4O5Na (M+Na)+: 525.3053; found, 525.3054.
5'b 淡粉色粉末状固体,,Mp: 60-61℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.52 (s, 1H), 7.34 (s, 5H), 5.43 (d, J = 8.6 Hz, 1H), 4.72 (dt, J = 17.4, 9.3 Hz, 3H), 4.55 (d, J = 11.8 Hz, 1H), 4.34 (t, J = 7.3 Hz, 2H), 4.22 (dd, J = 8.3, 3.4 Hz, 1H), 4.01 – 3.92 (m, 2H), 3.89 – 3.77 (m, 2H), 3.74 (d, J = 10.6 Hz, 1H), 3.64 (dd, J = 10.5, 3.7 Hz, 1H), 1.92 (d, J = 6.6 Hz, 2H), 1.48 (d, J = 18.3 Hz, 9H), 1.30 (dd, J = 16.7, 8.6 Hz, 10H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3,ppm) : δ 155.29, 144.44, 137.70, 128.43, 127.82, 122.24, 85.70, 83.98, 79.43, 73.04, 71.71, 70.56, 65.09, 55.79, 50.41, 31.70, 30.34, 29.04, 28.96, 28.43, 26.51, 22.60, 14.07. HRMS (IES) : m/z calcd for C28H44N4O5Na (M+Na)+: 539.3209; found, 539.3207.
5'c 白色粉末状固体,Mp: 78-79℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.50 (s, 1H), 7.33 (d, J = 5.2 Hz, 5H), 5.42 (d, J = 8.7 Hz, 1H), 4.71 (dt, J = 17.4, 9.5 Hz, 3H), 4.54 (d, J = 11.8 Hz, 1H), 4.32 (t, J = 7.3 Hz, 2H), 4.20 (dd, J = 8.6, 3.5 Hz, 1H), 4.03 – 3.92 (m, 2H), 3.90 – 3.76 (m, 2H), 3.76 – 3.68 (m, 1H), 3.62 (dd, J = 10.6, 3.8 Hz, 1H), 1.90 (d, J = 6.7 Hz, 2H), 1.46 (d, J = 18.6 Hz, 9H), 1.27 (dd, J = 26.9, 11.7 Hz, 12H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 155.29, 144.43, 137.69, 128.43, 127.82, 122.24, 85.69, 83.98, 79.44, 73.05, 71.71, 70.55, 65.09, 55.78, 50.41, 31.80, 30.35, 29.71, 29.34, 29.18, 29.01, 28.43, 26.51, 22.64, 14.11. HRMS (IES) : m/z calcd for C29H47N4O5 (M+H)+: 531.3541; found, 531.3547.
5'd 白色粉末状固体,Mp: 73-74℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.51 (d, J = 6.8 Hz, 1H), 7.33 (d, J = 7.1 Hz, 5H), 5.42 (s, 1H), 4.73 (dt, J = 11.7, 6.7 Hz, 3H), 4.55 (dd, J = 11.7, 7.3 Hz, 1H), 4.33 (q, J = 7.3 Hz, 2H), 4.21 (s, 1H), 3.98 (s, 2H), 3.84 (dd, J = 16.3, 8.4 Hz, 2H), 3.75 (d, J = 8.2 Hz, 1H), 3.69 – 3.55 (m, 1H), 1.90 (d, J = 6.0 Hz, 2H), 1.45 (d, J = 6.9 Hz, 9H), 1.28 (t, J = 12.9 Hz, 14H), 0.89 (q, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 155.28, 144.43, 137.69, 128.42, 127.81, 122.22, 85.70, 83.98, 79.43, 73.04, 71.71, 70.55, 65.09, 55.77, 50.41, 31.85, 30.34, 29.47, 29.39, 29.25, 29.01, 28.43, 26.52, 22.67, 14.12. HRMS (IES) : m/z calcd for C30H48N4O5Na (M+Na)+, 567.3522; found, 567.3521.
5'e 白色粉末状固体,Mp: 71-72℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.50 (s, 1H), 7.33 (d, J = 5.4 Hz, 5H), 5.41 (d, J = 8.6 Hz, 1H), 4.71 (dt, J = 17.3, 9.4 Hz, 3H), 4.54 (d, J = 11.8 Hz, 1H), 4.33 (dd, J = 14.0, 7.1 Hz, 2H), 4.19 (dd, J = 10.7, 7.1 Hz, 1H), 4.00 – 3.92 (m, 2H), 3.87 – 3.76 (m, 2H), 3.73 (d, J = 10.5 Hz, 1H), 3.62 (dd, J = 10.6, 3.8 Hz, 1H), 1.90 (d, J = 6.6 Hz, 2H), 1.44 (s, 9H), 1.35 – 1.18 (m, 18H), 0.93 – 0.82 (m, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 155.29, 144.43, 137.69, 128.43, 127.82, 122.23, 85.69, 83.98, 79.44, 73.05, 71.71, 70.55, 65.09, 55.78, 50.42, 31.91, 30.36, 29.71, 29.60, 29.53, 29.40, 29.34, 29.02, 28.43, 26.52, 22.69, 14.13.
HRMS (IES) : m/z calcd for C32H52N4O5Na (M+Na)+: 595.3835; found, 595.3838.
5'f 白色粉末状固体,Mp: 58-59℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.51 (s, 1H), 7.34 (s, 5H), 5.43 (d, J = 8.6 Hz, 1H), 4.73 (dd, J = 15.4, 8.5 Hz, 2H), 4.55 (d, J = 11.8 Hz, 1H), 4.33 (t, J = 7.3 Hz, 2H), 4.22 (d, J = 5.1 Hz, 1H), 3.98 (s, 2H), 3.89 – 3.79 (m, 2H), 3.74 (d, J = 10.2 Hz, 1H), 3.70 – 3.59 (m, 1H), 1.90 (s, 2H), 1.45 (s, 9H), 1.30 (d, J = 26.2 Hz, 22H), 0.89 (t, J = 6.6 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 155.29, 144.44, 137.70, 128.41, 127.81, 122.22, 85.70, 83.97, 79.42, 73.01, 71.70, 70.55, 65.07, 55.81, 50.40, 31.91, 30.33, 29.67, 29.63, 29.59, 29.52, 29.38, 29.34, 29.00, 28.42, 26.51, 22.68, 14.12. HRMS (IES) : m/z calcd for C34H56N4O5Na (M+Na)+: 623.4148; found, 623.4148.
5'g 白色粉末状固体,Mp: 61-62℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.50 (s, 1H), 7.33 (d, J = 5.4 Hz, 5H), 5.41 (d, J = 8.5 Hz, 1H), 4.71 (dt, J = 17.4, 9.4 Hz, 3H), 4.54 (d, J = 11.8 Hz, 1H), 4.32 (t, J = 7.3 Hz, 2H), 4.25 – 4.16 (m, 1H), 4.01 – 3.90 (m, 2H), 3.89 – 3.77 (m, 2H), 3.72 (dd, J = 8.8, 4.4 Hz, 1H), 3.62 (dd, J = 10.6, 3.7 Hz, 1H), 1.90 (d, J = 6.6 Hz, 2H), 1.44 (s, 9H), 1.28 (d, J = 26.8 Hz, 26H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 155.29, 144.44, 137.70, 128.42, 127.81, 122.21, 85.70, 83.98, 79.43, 73.04, 71.71, 70.56, 65.10, 55.80, 50.41, 31.93, 30.35, 29.69, 29.66, 29.61, 29.53, 29.40, 29.37, 29.02, 28.43, 26.53, 22.70, 14.13. HRMS (IES) : m/z calcd for C36H60N4O5Na (M+ Na)+: 651.4461; found, 651.4463.
5'h 白色粉末状固体,Mp: 74-75℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.52 (s, 1H), 7.34 (s, 5H), 5.44 (d, J = 8.5 Hz, 1H), 4.81 – 4.64 (m, 3H), 4.55 (d, J = 11.8 Hz, 1H), 4.34 (t, J = 7.3 Hz, 2H), 4.22 (d, J = 5.0 Hz, 1H), 3.99 (s, 2H), 3.91 – 3.77 (m, 2H), 3.74 (d, J = 10.5 Hz, 1H), 3.68 – 3.59 (m, 1H), 1.92 (d, J = 6.4 Hz, 2H), 1.45 (s, 9H), 1.37 – 1.22 (m, 30H), 0.90 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 155.30, 144.43, 137.70, 128.42, 127.81, 122.25, 85.70, 83.97, 79.44, 73.00, 71.71, 70.56, 65.05, 55.83, 50.42, 31.92, 30.33, 29.69, 29.65, 29.60, 29.53, 29.39, 29.36, 29.01, 28.42, 27.41, 26.52, 22.69, 14.12. HRMS (IES) : m/z calcd for C38H64N4O5Na (M+Na)+: 679.4778; found, 679.4778.
表2中化合物的核磁数据选择性表述如下:
6a 无色油状物,1H NMR (400 MHz, Acetone-d 6, ppm) : δ 7.94 (s, 1H), 4.70 – 4.56 (m, 2H), 4.47 (dd, J = 6.4, 3.5 Hz, 1H), 4.42 (t, J = 7.1 Hz, 2H), 4.07 – 4.01 (m, 1H), 3.83 – 3.75 (m, 2H), 3.65 – 3.57 (m, 2H), 3.54 (dd, J = 10.1, 5.0 Hz, 1H), 2.87 (s, 1H), 1.98 – 1.85 (m, 2H), 1.32 (ddd, J = 9.2, 5.7, 2.7 Hz, 10H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, Acetone-d 6, ppm) : δ 144.72, 122.88, 81.76, 81.11, 71.47, 68.90, 64.57, 64.37, 49.62, 31.51, 30.19, 28.42, 26.23, 22.33, 13.44. HRMS (IES) : m/z calcd for C15H29N4O3 (M+H)+: 313.2235; found, 313.2235.
6b 黄色油状物,1H NMR (400 MHz, Acetone-d 6, ppm) : δ 7.91 (s, 1H), 4.70 – 4.52 (m, 2H), 4.51 – 4.36 (m, 3H), 4.10 – 3.98 (m, 1H), 3.87 – 3.69 (m, 2H), 3.66 – 3.56 (m, 2H), 3.52 (dd, J = 10.1, 5.0 Hz, 1H), 2.78 (s, 2H), 1.91 (dd, J = 13.9, 7.0 Hz, 2H), 1.30 (dd, J = 13.4, 5.4 Hz, 12H), 0.87 (t, J = 6.7 Hz, 3H). 13C NMR (100 MHz, Acetone-d 6,ppm) : δ 144.73, 122.87, 81.77, 81.11, 71.46, 68.90, 64.55, 64.38, 49.62, 31.61, 30.19, 26.28, 22.39, 13.47. HRMS (IES) : m/z calcd for C16H31N4O3 (M+H)+: 327.2391; found, 327..2394.
6c 淡黄色粉末状固体,Mp: 51-52℃; 1H NMR (400 MHz, Acetone-d 6, ppm) : δ 7.93 (s, 1H), 4.71 – 4.56 (m, 2H), 4.48 (dd, J = 6.4, 3.5 Hz, 1H), 4.42 (t, J = 7.1 Hz, 2H), 4.12 – 3.98 (m, 1H), 3.79 (dt, J = 7.1, 5.0 Hz, 2H), 3.64 – 3.57 (m, 2H), 3.55 (dd, J = 10.1, 5.0 Hz, 1H), 1.99 – 1.85 (m, 2H), 1.34 (dd, J = 15.0, 9.3 Hz, 14H), 0.90 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, Acetone-d 6, ppm) : δ 144.72, 122.85, 81.77, 81.13, 71.43, 68.87, 64.51, 64.39, 49.62, 31.68, 30.19, 29.25, 29.06, 28.85, 26.27, 22.42, 13.48. HRMS (IES) : m/z calcd for C17H33N4O3 (M+H)+, 341.2547; found, 341.2554.
6d 白色粉末状固体,Mp: 54-55℃; 1H NMR (400 MHz, Acetone-d 6, ppm) : δ 7.93 (s, 1H), 4.62 (q, J = 12.2 Hz, 2H), 4.48 (dd, J = 6.4, 3.5 Hz, 1H), 4.42 (t, J = 7.1 Hz, 2H), 4.14 – 3.94 (m, 1H), 3.83 – 3.70 (m, 2H), 3.64 – 3.59 (m, 2H), 3.56 – 3.51 (m, 1H), 2.01 – 1.82 (m, 2H), 1.43 – 1.25 (m, 16H), 0.90 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, Acetone-d 6, ppm) : δ 144.73, 122.85, 81.77, 81.12, 71.45, 68.89, 64.53, 64.39, 49.62, 31.73, 30.19, 29.30, 29.13, 28.85, 26.28, 22.44, 13.49. HRMS (IES) : m/z calcd for C18H35N4O3 (M+H)+, 355.2704; found, 355.2702.
6e 黄色粉末状固体,Mp: 57-58℃; 1H NMR (400 MHz, Acetone-d 6, ppm) : δ 7.95 (s, 1H), 4.68 – 4.58 (m, 2H), 4.54 (dd, J = 6.2, 3.3 Hz, 1H), 4.42 (t, J = 7.1 Hz, 2H), 4.18 – 4.08 (m, 1H), 3.88 (d, J = 10.3 Hz, 1H), 3.80 (dd, J = 13.9, 7.2 Hz, 1H), 3.64 (t, J = 7.6 Hz, 2H), 3.60 – 3.53 (m, 1H), 1.98 – 1.86 (m, 2H), 1.33 (d, J = 18.4 Hz, 20H), 0.89 (d, J = 6.8 Hz, 3H). 13C NMR (100 MHz, Acetone-d 6, ppm) : δ 144.66, 122.93, 81.69, 81.25, 71.12, 68.71, 64.36, 64.20, 49.65, 31.76, 30.20, 29.48, 29.32, 28.88, 26.29, 22.46, 13.52. HRMS (IES) : m/z calcd for C20H39N4O3 (M+H)+, 383.3017; found, 383.3019.
6f 白色粉末状固体,Mp: 63-64℃;1H NMR (400 MHz, CDCl3, ppm) : δ 7.57 (s, 1H), 4.70 (q, J = 12.4 Hz, 2H), 4.33 (t, J = 7.3 Hz, 2H), 4.04 (dd, J = 9.1, 5.7 Hz, 1H), 3.94 – 3.89 (m, 1H), 3.86 (dd, J = 8.6, 4.7 Hz, 1H), 3.73 (qd, J = 10.4, 4.1 Hz, 2H), 3.63 (dd, J = 9.1, 4.3 Hz, 1H), 3.35 (dd, J = 9.6, 4.2 Hz, 1H), 2.75 (s, 3H), 1.96 – 1.83 (m, 2H), 1.39 – 1.18 (m, 24H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 144.59, 122.47, 84.10, 79.66, 74.04, 70.73, 64.72, 59.71, 50.44, 31.91, 30.27, 29.67, 29.63, 29.60, 29.52, 29.39, 29.34, 29.00, 26.51, 22.68, 14.11. HRMS (IES) : m/z calcd for C22H43N4O3 (M+H)+, 411.3330; found, 411.3337.
6g 黄色粉末状固体,Mp: 70-71℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.55 (s, 1H), 4.72 (q, J = 12.6 Hz, 2H), 4.33 (t, J = 7.3 Hz, 2H), 4.12 (dd, J = 8.0, 3.5 Hz, 1H), 4.06 (dd, J = 10.0, 4.7 Hz, 1H), 4.00 – 3.91 (m, 1H), 3.86 (dd, J = 10.2, 4.7 Hz, 1H), 3.77 (dd, J = 10.2, 5.7 Hz, 1H), 3.65 – 3.53 (m, 2H), 2.51 (s, 3H), 1.96 – 1.83 (m, 2H), 1.43 – 1.21 (m, 28H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 144.75, 122.18, 80.69, 72.42, 71.82, 69.60, 64.86, 54.40, 50.41, 31.91, 30.26, 29.67, 29.64, 29.59, 29.51, 29.37, 29.34, 28.99, 26.49, 22.68, 14.11.
HRMS (IES) : m/z calcd for C24H47N4O3 (M+H)+: 439.3643; found, 439.3647.
6h 白色固体, Mp: 49-50℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.57 (s, 1H), 4.80 – 4.65 (m, 2H), 4.33 (t, J = 7.3 Hz, 2H), 4.06 (dd, J = 6.2, 4.6 Hz, 1H), 3.90 (d, J = 10.6 Hz, 1H), 3.89 – 3.82 (m, 1H), 3.76 – 3.68 (m, 2H), 3.61 (dd, J = 10.6, 4.6 Hz, 1H), 1.96 – 1.85 (m, 2H), 1.34 – 1.20 (m, 32H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3,ppm) : δ 145.00, 122.29, 81.68, 80.79, 71.54, 69.40, 65.05, 64.78, 50.34, 31.93, 30.31, 29.70, 29.66, 29.61, 29.53, 29.39, 29.37, 29.02, 26.52, 22.70, 14.13. HRMS (IES) : m/z calcd for C26H51N4O3 (M+H)+, 467.3956; found, 467.3962.
6'a 黄色油状物,1H NMR (400 MHz, Acetone-d 6, ppm) : δ 7.96 (d, J = 9.8 Hz, 1H), 4.63 (s, 2H), 4.42 (t, J = 7.2 Hz, 2H), 4.01 (ddd, J = 11.7, 9.8, 6.6 Hz, 2H), 3.88 (ddd, J = 7.7, 5.7, 3.9 Hz, 1H), 3.73 – 3.68 (m, 1H), 3.66 (dd, J = 7.2, 2.7 Hz, 1H), 3.64 – 3.59 (m, 1H), 1.98 – 1.88 (m, 2H), 1.39 – 1.24 (m, 8H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, Acetone-d 6, ppm) : δ 144.72, 122.96, 84.06, 78.89, 71.66, 70.87, 67.70, 64.42, 49.66, 31.50, 30.17, 28.42, 26.24, 22.33, 13.44. HRMS (IES) : m/z calcd for C15H29N4O3 (M+H)+: 313.2235; found, 313.2235.
6'b 黄色油状物,1H NMR (400 MHz,Acetone-d 6, ppm) : δ 7.94 (s, 1H), 4.63 (s, 2H), 4.42 (t, J = 7.2 Hz, 2H), 4.06 – 3.95 (m, 3H), 3.89 (dd, J = 5.9, 4.2 Hz, 1H), 3.70 (dd, J = 10.5, 4.2 Hz, 1H), 3.67 – 3.59 (m, 2H), 1.99 – 1.86 (m, 5H), 1.56 – 1.17 (m, 12H), 0.89 (t, J = 6.9 Hz, 3H). 13C NMR (100 MHz, Acetone-d 6, ppm) : δ 144.73, 122.93, 84.07, 78.95, 71.69, 70.87, 67.73, 64.42, 49.65, 31.60, 30.16, 26.27, 22.38, 21.53, 13.45. HRMS (IES) : m/z calcd for C16H31N4O3 (M+H)+: 327.2391; found, 327.2394.
6'c 无色油状物, 1H NMR (400 MHz, Acetone-d 6, ppm) : δ 7.94 (s, 1H), 4.63 (s, 2H), 4.42 (t, J = 7.2 Hz, 2H), 4.05 – 3.97 (m, 2H), 3.89 (dt, J = 10.0, 5.1 Hz, 1H), 3.73 – 3.68 (m, 1H), 3.67 – 3.60 (m, 2H), 1.93 (dd, J = 14.1, 7.1 Hz, 2H), 1.42 – 1.25 (m, 14H), 0.90 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, Acetone-d 6, ppm) : δ 144.72, 122.93, 84.09, 78.94, 71.69, 70.86, 67.72, 64.42, 49.65, 31.68, 30.17, 29.25, 29.06, 28.85, 26.27, 22.41, 13.47. HRMS (IES) : m/z calcd for C17H33N4O3 (M+H)+: 341.2547; found, 341.2552.
6'd 淡黄色油状物,1H NMR (400 MHz, Acetone-d 6, ppm) : δ 7.94 (s, 1H), 4.63 (s, 2H), 4.42 (t, J = 7.2 Hz, 2H), 4.01 (dd, J = 8.2, 3.7 Hz, 2H), 3.89 (dt, J = 10.0, 5.1 Hz, 1H), 3.70 (dd, J = 10.5, 4.1 Hz, 1H), 3.63 (dt, J = 13.8, 5.1 Hz, 2H), 1.96 – 1.89 (m, 2H), 1.88 (s, 3H), 1.41 – 1.26 (m, 16H), 0.90 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, Acetone-d 6, ppm) : δ 144.73, 122.93, 84.07, 78.93, 71.68, 70.88, 67.74, 64.43, 49.66, 31.72, 29.30, 29.12, 28.85, 26.28, 22.43, 13.48. HRMS (IES) : m/z calcd for C18H35N4O3 (M+H)+: 355.2704; found, 355.2707.
6'e 黄色油状物, 1H NMR (400 MHz, CDCl3, ppm) : δ 7.57 (s, 1H), 4.78 – 4.63 (m, 2H), 4.34 (t, J = 7.3 Hz, 2H), 4.05 (dd, J = 9.1, 5.7 Hz, 1H), 3.95 – 3.89 (m, 1H), 3.86 (dd, J = 8.7, 4.7 Hz, 1H), 3.79 – 3.68 (m, 2H), 3.64 (dd, J = 9.1, 4.4 Hz, 1H), 3.36 (dd, J = 9.6, 4.2 Hz, 1H), 2.59 (s, 3H), 1.97 – 1.83 (m, 2H), 1.38 – 1.18 (m, 20H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 144.60, 122.45, 84.06, 79.74, 74.04, 70.73, 64.72, 59.70, 50.44, 31.89, 30.27, 29.63, 29.59, 29.52, 29.38, 29.32, 29.00, 26.51, 22.67, 14.11. HRMS (IES) : m/z calcd for C20H39N4O3 (M+H)+: 383.3017; found, 383.3021.
6'f 白色粉末状固体,Mp:76-77℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.58 (s, 1H), 4.69 (q, J = 12.3 Hz, 2H), 4.33 (t, J = 7.3 Hz, 2H), 4.04 (dd, J = 9.2, 5.6 Hz, 1H), 3.99 – 3.92 (m, 1H), 3.87 (dd, J = 8.4, 4.5 Hz, 1H), 3.73 (qd, J = 10.5, 4.0 Hz, 2H), 3.66 (dd, J = 9.2, 4.1 Hz, 1H), 3.37 (dd, J = 9.1, 3.8 Hz, 1H), 3.10 (s, 4H), 1.94 – 1.85 (m, 2H), 1.29 (d, J = 24.8 Hz, 22H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3. ppm) : δ 144.48, 122.54, 84.16, 79.24, 73.72, 70.61, 64.66, 59.55, 50.45, 31.91, 30.26, 29.67, 29.63, 29.60, 29.52, 29.39, 29.34, 29.00, 26.51, 22.67, 14.11. HRMS (IES) : m/z calcd for C22H43N4O3 (M+H)+: 411.3330; found, 411.3337.
6'g 黄色粉末状固态Mp:81-82℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.57 (s, 1H), 4.77 – 4.63 (m, 2H), 4.34 (t, J = 7.3 Hz, 2H), 4.05 (dd, J = 9.1, 5.7 Hz, 1H), 3.91 (dd, J = 11.1, 7.2 Hz, 1H), 3.86 (dd, J = 8.7, 4.7 Hz, 1H), 3.80 – 3.68 (m, 2H), 3.63 (dd, J = 9.1, 4.4 Hz, 1H), 3.35 (dd, J = 9.6, 4.2 Hz, 1H), 2.59 (s, 3H), 1.89 (dd, J = 13.6, 6.7 Hz, 2H), 1.36 – 1.20 (m, 26H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 144.60, 122.47, 84.10, 79.69, 74.08, 70.74, 64.72, 59.72, 50.44, 31.91, 30.28, 29.68, 29.65, 29.60, 29.53, 29.39, 29.35, 29.01, 26.51, 22.68, 14.11. HRMS (IES) : m/z calcd for C24H47N4O3 (M+H)+: 439.3643; found, 439.3649.
6'h 白色粉末状固体,Mp:67-68℃; 1H NMR (400 MHz, CDCl3, ppm) : δ 7.57 (s, 1H), 4.78 – 4.64 (m, 2H), 4.34 (t, J = 7.3 Hz, 2H), 4.05 (dd, J = 9.1, 5.7 Hz, 1H), 3.95 – 3.91 (m, 1H), 3.90 – 3.84 (m, 1H), 3.74 (t, J = 4.0 Hz, 2H), 3.65 (dd, J = 9.1, 4.3 Hz, 1H), 3.37 (d, J = 5.4 Hz, 1H), 2.64 (s, 3H), 1.98 – 1.81 (m, 2H), 1.36 – 1.22 (m, 30H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3, ppm) : δ 144.59, 122.44, 84.08, 79.70, 74.00, 70.72, 64.73, 59.69, 50.44, 31.92, 30.28, 29.69, 29.65, 29.61, 29.54, 29.40, 29.36, 29.01, 26.51, 22.68, 14.12. HRMS (IES) : m/z calcd for C26H51N4O3 (M+H)+: 467.3956; found, 467.3962.。
抗肿瘤活性评价方法:
本发明中抗肿瘤活性评价方法采用MTT法,具体操作如下:取对数期生长的人癌细胞系,细化后计数。3×103个/孔(190μL)接种于96孔细胞培养板中。24h待细胞贴壁后加入8个不同浓度的待测样品溶液,使待测样品在每组孔里的最终浓度分别为0.5μg/ml、1μg/ml、2μg/ml、4μg/ml、8μg/ml、16μg/ml、32μg/ml和64μg/ml,每组至少有三个平行孔,处理细胞到指定时间。测定前每孔加入20μLMTT溶液(MTT用无菌PBS缓冲液配成5mg/mL的溶液),37℃孵育4h后,小心吸出上清液,每孔加入150μL的DMSO,震荡15min,使结晶物充分溶解、均匀。用酶标仪测定490nm处吸光度值。将各测试孔的OD值减去本底OD值(完全培养基加MTT,无细胞),各平行孔的OD值取平均值。细胞存活率% = (加药细胞OD值-本底OD值)/(对照细胞OD值-本底OD值)×100%。每个检测点取三个平行孔的平均值,绘制抑制曲线,计算IC50值。
化合物6a-6h的抗癌活性数据(IC50, μmol/L,48h)
化合物 | EC-9706 | MGC-803 | MCF-7 |
6a | >128 | >128 | >128 |
6b | 44.27±3.55 | 70.42±4.17 | 28.119±2.95 |
6c | 20.13±2.46 | 13.81±1.98 | 12.44±1.84 |
6d | 15.57±2.09 | 8.78±1.39 | 9.64±1.51 |
6e | 15.99±2.05 | 21.39±2.39 | 2.21±0.19 |
6f | 7.83±1.23 | 8.21±1.29 | 1.85±0.29 |
6g | 19.99±2.15 | 27.884±2.48 | 3.301±0.37 |
6h | 17.80±1.97 | 15.40±1.83 | 7.58±1.17 |
化合物6'a-6'h的抗癌活性数据(IC50, μmol/L,48h)
化合物 | EC-9706 | MGC-803 | MCF-7 |
6'a | >128 | >128 | >128 |
6'b | >128 | >128 | >128 |
6'c | >128 | >128 | >128 |
6'd | 43.10±3.34 | 57.39±3.69 | 44.99±2.88 |
6'e | 93.76±3.90 | 115.08±1.60 | 2.62±0.06 |
6'f | 6.68±1.07 | 8.79±1.36 | 2.26±0.01 |
6'g | 6.31±1.01 | 5.34±0.84 | 2.26±0.01 |
6'h | 2.29±0.06 | 3.11±0.35 | 1.93±0.09 |
由上表可以看出,以上两个系列的化合物活性都是随着链长的增加而增加,且大部分化合物都对测试的3种癌细胞都显示出较好的细胞毒活性,尤其系列6'a-6'h中,化合物6'f, 6'g和6'h对三种测试癌细胞的IC50都在10μmol以下。
Claims (6)
1.一类Jaspine B三氮唑类衍生物,其特征在于,具有如下结构通式:
其中n为6、7、8、9、11、13、15或17。
2.一类3-epi Jaspine B三氮唑类衍生物,其特征在于,具有如下结构通式:
其中n为6、7、8、9、11、13、15或17。
3.一种制备如权利要求1所述的Jaspine B三氮唑类衍生物的方法,通过以下步骤实现:(1)在溶剂中将化合物1还原得到化合物2,所用到的还原剂为KBH4或NaBH4, 所选用的溶剂为甲醇或乙醇;(2)溶剂中,化合物2在碱性条件下与溴丙炔反应得到化合物3,所用的碱为NaOH、KOH或K2CO3;所选用的溶剂为乙腈;(3)化合物3先在三苯基膦,四氢呋喃和水的体系下还原叠氮基团,再用Boc保护氨基得到化合物4;(4)溶剂中,将化合物4在催化剂的作用下与不同链长的烷基叠氮反应,得到化合物5a-5h;催化剂选择抗坏血酸钠与无水硫酸铜混合物,溶剂选择四氢呋喃与水混合物;
其中n为6、7、8、9、11、13、15或17;
所述烷基叠氮选自庚烷叠氮、辛烷叠氮、壬烷叠氮、癸烷叠氮、十二烷基叠氮、十四烷基叠氮、十六烷基叠氮或十八烷基叠氮;
(5)溶剂中,将化合物5a-5h在酸的作用下以及催化剂的作用下合成化合物6a-6h;所述溶剂选自甲醇,乙醇,乙酸乙酯;酸选自盐酸或三氟乙酸,催化剂选择Pd/C或Pd(OH)2 ;
。
4.一种制备如权利要求2所述的3-epi Jaspine B三氮唑类衍生物的方法,其特征在于,通过以下步骤实现:(1)在溶剂中将化合物1′还原得到化合物2′,所用到的还原剂为KBH4或NaBH4, 所选用的溶剂为甲醇或乙醇;(2)溶剂中,化合物2′在碱性条件下与溴丙炔反应得到化合物3′,所用的碱为NaOH、 KOH或K2CO3;所选用的溶剂为乙腈;(3)化合物3′先在三苯基膦,四氢呋喃和水的体系下还原叠氮基团,再用Boc保护氨基得到化合物4′;(4)溶剂中,将化合物4′在催化剂的作用下与不同链长的烷基叠氮反应,得到化合物5′a-5′h;催化剂选择抗坏血酸钠与无水硫酸铜混合物,溶剂选择四氢呋喃与水混合物;
其中n为6、7、8、9、11、13、15或17;
所述烷基叠氮选自庚烷叠氮、辛烷叠氮、壬烷叠氮、癸烷叠氮、十二烷基叠氮、十四烷基叠氮、十六烷基叠氮或十八烷基叠氮;
(5)溶剂中,将化合物5'a-5'h在酸的作用下以及催化剂的作用下合成化合物6'a-6'h;所述溶剂选自甲醇,乙醇,乙酸乙酯;酸选自盐酸或三氟乙酸,催化剂选择Pd/C或 Pd(OH)2 ;
。
5.如权利要求1或2所述的Jaspine B、3-epi Jaspine B三氮唑类化合物在制备药物中的应用,其特征在于,以其为活性成份,将其用于制备治疗乳腺癌、食管癌、胃癌、前列腺癌、子宫癌、卵巢癌、子宫颈癌、结肠癌、直肠癌、甲状腺癌、肺癌、肝癌、甲状腺癌、睾丸癌、肾癌、膀胱癌、小肠癌、胰腺癌或白血病药物中。
6.如权利要求1或2所述的Jaspine B、3-epi Jaspine B三氮唑类化合物在制备药物中的应用,其特征在于,以其为活性成份,将其用于制备治疗乳腺癌、食管癌或胃癌药物中。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310278916.9A CN103304549B (zh) | 2013-07-04 | 2013-07-04 | Jaspine B、3-epi Jaspine B三氮唑类衍生物、其制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310278916.9A CN103304549B (zh) | 2013-07-04 | 2013-07-04 | Jaspine B、3-epi Jaspine B三氮唑类衍生物、其制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103304549A CN103304549A (zh) | 2013-09-18 |
CN103304549B true CN103304549B (zh) | 2015-09-02 |
Family
ID=49130306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310278916.9A Active CN103304549B (zh) | 2013-07-04 | 2013-07-04 | Jaspine B、3-epi Jaspine B三氮唑类衍生物、其制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103304549B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105693660B (zh) * | 2016-03-30 | 2018-04-13 | 郑州大学 | Jaspine B、3‑epi Jaspine B氧代类似物、其制备方法及应用 |
CN107011292B (zh) * | 2017-04-12 | 2019-06-07 | 郑州大学 | Jaspine B、3-epi-Jaspine B氮代类似物、其制备方法及应用 |
CN107629100B (zh) * | 2017-08-10 | 2021-03-26 | 河南师范大学 | 一类包含三氮唑衍生物二核苷酸和肽缀合物及其合成方法 |
CN110330452A (zh) * | 2019-06-12 | 2019-10-15 | 山东省医学科学院药物研究所(山东省抗衰老研究中心、山东省新技术制药研究所) | 四氢吡咯烷类化合物或其药学上可接受的盐及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010107251A2 (ko) * | 2009-03-18 | 2010-09-23 | 가톨릭대학교 산학협력단 | 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물 |
CN102382081A (zh) * | 2011-09-19 | 2012-03-21 | 郑州大学 | 抗肿瘤活性天然产物jaspine B和3-epi jaspine B关键中间体的合成方法 |
-
2013
- 2013-07-04 CN CN201310278916.9A patent/CN103304549B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010107251A2 (ko) * | 2009-03-18 | 2010-09-23 | 가톨릭대학교 산학협력단 | 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물 |
CN102382081A (zh) * | 2011-09-19 | 2012-03-21 | 郑州大学 | 抗肿瘤活性天然产物jaspine B和3-epi jaspine B关键中间体的合成方法 |
Non-Patent Citations (4)
Title |
---|
1, 2, 3-三唑类化合物在医药领域的研究新进展;魏金建 等;《中国药学杂志》;20110430;第46卷(第7期);481-485 * |
Ahmed Kamal 等.Synthesis of 1,2,3-triazole-linked pyrrolobenzodiazepine conjugates employing ‘click’ chemistry: DNA-binding affinity and anticancer activity.《Bioorganic Medicinal Chemistry Letters》.2007,第18卷1468-1473. * |
Flexible and enantioselective access to jaspine B and biologically active chain-modified analogues thereof;Yahya Salma 等;《Org. Biomol. Chem.》;20100524;第8卷;3227-3243 * |
新型核苷和单糖1,2,3-三唑寡聚缀合物的合成及抗肿瘤活性;金培元 等;《有机化学》;20120915;第32卷;1673-1677 * |
Also Published As
Publication number | Publication date |
---|---|
CN103304549A (zh) | 2013-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017148193A1 (zh) | 一类含有生物活性基团的四价铂配合物及其制备方法 | |
CN103304549B (zh) | Jaspine B、3-epi Jaspine B三氮唑类衍生物、其制备方法及其应用 | |
Şahin et al. | Synthesis, characterization and anticancer activity of allyl substituted N-Heterocyclic carbene silver (I) complexes | |
JP6159818B2 (ja) | 抗腫瘍二価白金錯体並びに錯体および錯体のリガンドの製造方法 | |
CN102863376B (zh) | N-取代甲基-3,5-双取代苄叉基-4-哌啶酮及制备和应用 | |
CN103113414A (zh) | 一种芳基钌配合物及其制备方法和用途 | |
Iqbal et al. | Substitution of the chlorido ligand for PPh3 in anticancer organoruthenium complexes of sulfonamide-functionalized pyridine-2-carbothioamides leads to high cytotoxic activity | |
CN104523664A (zh) | 姜黄素类抗肿瘤药物及其应用 | |
CN102964387B (zh) | 一种有机金属钌离子对化合物及其制备方法和用途 | |
CN102731454B (zh) | 去氢木香烃内酯衍生物,其药物组合物及其制备方法和用途 | |
CN104003966B (zh) | 5,7,2,,4,-四羟基-3-烃基黄酮类似物及其制备方法和应用 | |
CN106543234B (zh) | 以饱和链为桥的手性双核铂配合物及其制备方法和应用 | |
US9822071B2 (en) | Anticancer miliusane lactams | |
CN100503539C (zh) | 一种具有抗肿瘤活性的二苯乙烯类化合物及其制备方法 | |
CN104592182A (zh) | 一种咖啡酸苯乙酯类化合物及其制备方法及应用 | |
CN107827934A (zh) | 具有抗癌活性的四价铂配合物、制备方法及应用 | |
US9695141B2 (en) | Anticancer miliusane derivatives | |
CN105693660A (zh) | Jaspine B、3-epi Jaspine B氧代类似物、其制备方法及应用 | |
Tian et al. | Synthesis and anticancer activity of diam (m) ine platinum (II) complexes with 3-oxo-cyclobutane-1, 1-dicarboxylate as the leaving group | |
CN104072443A (zh) | N-取代哌嗪氨荒酸铋(ⅲ)配合物及其制备方法和在制备抗肿瘤药物中的应用 | |
CN103755664A (zh) | 4-芳基噻(硒)唑类化合物及其用途 | |
CN101104609B (zh) | 茄呢基多胺衍生物、制备及其应用 | |
CN104974135B (zh) | 靶向dna具有抗肿瘤活性的含萘二酰亚胺结构的塞来昔布衍生物、药物组合物及其制备方法和应用 | |
CN103910691A (zh) | 卤代苯基查尔酮衍生物及其制备方法和应用 | |
CN104341407A (zh) | 喹唑啉类化合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |